SUPREME COURT CHALLENGES INDIA’S MEDICINE PRICING SYSTEM AS PATIENTS FACE STEEP RETAIL MARK-UPS
October 27, 2026
NEW DELHI, OCTOBER 27, 2026: The Supreme Court on Tuesday questioned the Union government over the enormous difference between the prices at which medicines are supplied to retailers and the maximum retail prices charged to consumers, asking why the country’s pharmaceutical pricing system appeared to favour manufacturers rather than patients.
A bench comprising Justices Vikram Nath and Sandeep Mehta raised the concerns while hearing two petitions challenging the high cost of medicines and seeking stronger regulation of drug prices. The judges questioned whether the existing regulatory framework was adequately protecting ordinary citizens from excessive mark-ups on essential and life-saving treatments.
The bench expressed particular concern about the functioning of the National Pharmaceutical Pricing Authority (NPPA), observing that the body appeared to be ineffective in addressing the problem. The judges questioned why the government was allowing such substantial price differences to persist despite having regulatory oversight of the pharmaceutical sector.
“The government is allowing this to happen,” the bench observed, stressing that the price disparities were occurring under the authorities’ watch. It questioned whether the existing system could continue without more effective intervention.
Appearing for the Centre, Additional Solicitor General Aishwarya Bhati defended the government’s approach, arguing that medicine prices in India were among the lowest internationally. She maintained that government policy did not seek to exercise comprehensive control over the entire pharmaceutical market, suggesting that regulation had to take account of the wider ecosystem through which medicines were produced and distributed.
The court’s questions followed its earlier criticism of the government’s decision to cap trade margins on non-scheduled anti-cancer medicines at 30 per cent of their maximum retail price. The measure, according to the government, was expected to generate annual savings of approximately ₹2,500 crore for patients. However, the bench had questioned why comparable safeguards could not be considered for other medicines.
The broader dispute concerns the gap between the price charged to retailers and the final price paid by patients. During earlier hearings, the court cited examples of cancer medicines and medical supplies being sold at prices substantially higher than their reported supply costs. It also raised concerns about the financial burden on families and taxpayers when expensive medicines are purchased through private hospitals or reimbursed under government-funded healthcare schemes.
The case brings into focus the balance between market competition, pharmaceutical distribution and public access to affordable treatment. The Centre has argued that excessive restrictions on trade margins could affect the availability and distribution of medicines, including in remote areas. The court, however, has emphasised the need to ensure that the regulatory system does not leave patients exposed to unjustifiably high prices.
After hearing the arguments, the Supreme Court reserved its order. Its eventual decision could influence the direction of future debates over medicine-price regulation, the authority of the NPPA and the extent to which trade margins should be controlled across the pharmaceutical market.
At the heart of the proceedings lies a fundamental public-health question: how can India preserve a reliable supply of medicines while ensuring that patients are not forced to bear disproportionate costs for treatments they urgently need? The court’s scrutiny has placed that question firmly before the government, the pharmaceutical industry and the country’s drug-pricing regulators.
